Cardiovascular Outcome Evidence in ANVISA Approved Professional Prescribing Information for SGLT2 Inhibitors
This study found that the ANVISA-approved professional prescribing information for SGLT2 inhibitors (empagliflozin, dapagliflozin, and canagliflozin) varies significantly in how comprehensively and clearly it communicates cardiovascular outcome evidence compared to landmark clinical trials.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of people living with type 2 diabetes, the goal of treatment has shifted over the last two decades. It is no longer just about keeping blood sugar levels in a safe range. Doctors now know that people with this condition face a much higher risk of heart attacks, strokes, and heart failure. Because of this, new medicines were developed not only to lower sugar but to protect the heart and kidneys. One powerful group of these medicines, known as SGLT2 inhibitors, has been shown in major global studies to significantly reduce the risk of dying from heart problems or being hospitalized for heart failure. These drugs work by helping the kidneys remove extra sugar from the body through urine, but they also seem to offer a separate shield for the cardiovascular system.
However, a crucial question remains: how well does the official information given to doctors reflect these life-saving discoveries? In Brazil, the health regulatory agency, ANVISA, approves the package inserts that come with every medicine. These documents are the primary source of technical facts for physicians, guiding them on how to prescribe drugs safely and effectively. If the most important findings from the giant clinical trials are missing, vague, or buried in the text, doctors might not fully appreciate the heart-protecting benefits of these drugs. This gap between what science has proven and what the official paperwork says is the focus of a new study by researchers at the Federal University of São João Del-Rei. They wanted to see if the official instructions for three popular diabetes drugs accurately told the story of their heart benefits.
The researchers took a close look at the most recent official prescribing information available for three specific drugs: empagliflozin, dapagliflozin, and canagliflozin. They retrieved these documents from the government's public database on a single day in April 2026 to ensure they were comparing the latest versions. Their goal was not to test the drugs themselves or to see which one worked better in a patient. Instead, they treated the documents themselves as the subject of the study. They created a simple checklist to see how well each document reported on major heart events, such as heart attacks, strokes, and death from heart causes. They also checked if the documents included specific numbers showing how much the risk was reduced, if the information was easy to understand, and if the context explained who would benefit most from the treatment.
The results showed a clear and surprising difference in how these three drugs were described, even though they belong to the same family of medicines. The document for empagliflozin was the most complete. It listed all three major heart events, provided specific numbers showing the reduction in risk, and clearly explained the benefits in the context of patients with established heart disease. This matched the findings of the large global trial that tested this specific drug. The document for dapagliflozin took a different approach. It focused heavily on benefits related to heart failure and kidney health, which were the main successes of its own major trial. It mentioned the major heart events less prominently and did not provide the same level of detailed numbers as the first drug. The document for canagliflozin was the least informative regarding these specific outcomes; it did not provide any numerical estimates of heart risk reduction and omitted the detailed breakdown of the three major heart events entirely.
The study found that while two of the three documents mentioned heart benefits, only one provided the full quantitative picture that doctors might expect from the landmark trials. The researchers noted that these differences did not mean one drug was better or worse than the others in a patient's body. Instead, the variations reflected how the regulatory information was written and what specific outcomes were chosen to be highlighted in each document. For instance, the document for dapagliflozin was not "wrong" for focusing on heart failure, because that was the primary success of its testing, but it did not tell the whole story of the three-part heart event measure used in the broader field. The absence of numbers in the canagliflozin document was not a contradiction of the science, but simply a lack of reporting in that specific text.
This analysis highlights a quiet but important reality in medical regulation: the official instructions that guide daily medical practice do not always mirror the full depth of the scientific evidence behind them. The researchers concluded that while the documents were accurate, they varied significantly in how much detail they offered about heart protection. This suggests that the way scientific discoveries are translated into official drug information is not yet a uniform process. For doctors trying to make the best decisions for their patients, having consistent, clear, and complete information about heart benefits in every drug's package insert could be a vital step forward. The study does not claim that the drugs are failing or that the regulators are negligent, but it does point out that the story of heart protection is told with different levels of detail depending on which drug a doctor picks up.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.